Product Description
QLC1101 is an innovative small molecule inhibitor targeting KRAS G12D with independent intellectual property rights developed by Qilu Pharmaceutical Co., Ltd.QLC1101 can prevent GTP/GDP nucleotide exchange and/or the formation of KRAS G12D/GTP/RAF1 complex and inhibit mutant KRAS-dependent signal transduction by specifically binding to the KRAS G12D target, thereby inhibiting the generation of KRAS G12D mutant tumors. (Sourced from: https://clinicaltrials.gov/study/NCT06403735)
Mechanisms of Action: KRAS G12D Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Qilu
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
![Map of Global Clinical Trials for QLC-1101](https://pryzm-maps.s3.us-west-2.amazonaws.com/12current_maps.png)
Countries in Clinic: China
Active Clinical Trial Count: 1
Highest Development Phases
Phase 1: Colorectal Cancer|Non-Small-Cell Lung Cancer|Pancreatic Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
QLC1101-101 | P1 |
Recruiting |
Pancreatic Cancer|Non-Small-Cell Lung Cancer|Colorectal Cancer |
2026-05-31 |
34% |